VS411 Reduced Immune Activation and HIV-1 RNA Levels in 28 Days: Randomized Proof-Of-Concept Study for AntiViral-HyperActivation Limiting Therapeutics

PLoS ONE - United States
doi 10.1371/journal.pone.0047485